#ChugaiPharmaceuticalCoLtd

Chugai Pharmaceutical announced that Roche will discontinue clinical development of the anti-myostatin antibody emugrobart for spinal muscular atrophy and facioscapulohumeral muscular dystrophy. Development targeting obesity will continue.

F. Hoffmann-La Roche Ltd. announced its fiscal 2025 financial results. Chugai Pharmaceutical is a consolidated subsidiary of Roche Holdings, the parent company, holding 59.89% of issued shares as of the end of December 2025.

The fiscal year-end dividend for the term ending December 2025 is 147 yen per share (ordinary dividend 72 yen, 100th anniversary commemorative dividend 75 yen), raising the annual dividend to 272 yen. The total dividend amount is 241.92 billion yen, with an effective date of March 27, 2026.

Chugai Pharmaceutical will abolish the restricted stock compensation plan and introduce a trust-based stock compensation plan. Implementation is planned upon approval at the shareholders meeting on March 26, 2026.